Filament Health Corp (NEO:FH, OTCQB:FLHLF) terminated a special meeting seeking approval for a proposed arrangement, citing recent changes to financing and Nasdaq listing requirements.
The adjustments, prompted by the need to meet Nasdaq standards, led the Board to explore strategic options, including potential updates to financing and combination terms.
CEO Benjamin Lightburn highlighted the complexity of the deal and stressed the commitment to shareholder value. The company engaged Donohoe Advisory Associates for guidance on Nasdaq listing strategies.